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Sodium–glucose cotransporter (SGLT) inhibitors are new oral antidiabetes med-
ications shown to effectively reduce glycated hemoglobin (A1C) and glycemic
variability, blood pressure, and body weight without intrinsic properties to cause
hypoglycemia in people with type 1 diabetes. However, recent studies, particularly
in individualswith type1diabetes, havedemonstrated increases in theabsolute risk
of diabetic ketoacidosis (DKA). Some cases presented with near-normal blood
glucose levels or mild hyperglycemia, complicating the recognition/diagnosis of
DKAandpotentially delaying treatment. Several SGLT inhibitors are currently under
reviewby theU.S. Food andDrug Administration and European regulatory agencies
as adjuncts to insulin therapy in people with type 1 diabetes. Strategies must be
developed and disseminated to the medical community to mitigate the associated
DKA risk. This Consensus Report reviews current data regarding SGLT inhibitor use
and provides recommendations to enhance the safety of SGLT inhibitors in people
with type 1 diabetes.
Intensive insulin management remains the only option for effective treatment of
type 1 diabetes. However, fear of hypoglycemia (1–3) and weight gain (4) are often
barriers to optimal use of insulin therapy. Consequently, there exist an unmet
need and great patient interest in adjunct therapies of type 1 diabetes to improve
glycemic control without increasing the risk of hypoglycemia and weight gain. Most
noninsulin adjunctive therapies approved for type 2 diabetes are not effective in
type 1 diabetes. The only one approved in the U.S. is pramlintide, and it is not used
much clinically owing to its limited efficacy and unfavorable side effects. One novel
strategy studied to improve outcomes in patients with type 1 diabetes is the
addition of sodium–glucose cotransporter (SGLT) inhibitors as an adjunct to insulin
therapy.
SGLT2 inhibitors block the SGLT2 transporter in the proximal tubule of the kidney
resulting in glycosuria and natriuresis. SGLT112 inhibitors have the additional effect
of locally inhibiting SGLT1 in the gastrointestinal tract, delaying absorption of glucose
and galactose from the intestinal tract. The use of SGLT2 inhibitors in the setting of
type 2 diabetes is now recommended (5) to prevent major adverse cardiovascular
events (including mortality and hospitalizations for heart failure) in patients with
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established atherosclerotic cardiovascu-
lar disease as well as chronic kidney
disease, based on the results of the BI
10773 (Empagliflozin) Cardiovascular
Outcome Event Trial in Type 2 Diabetes
MellitusPatients (EMPA-REGOUTCOME)
(6,7) and theCanagliflozinCardiovascular
Assessment Study (CANVAS) (8,9). Sim-
ilar reductions in hospitalizations for
heart failure were seen in patients at
high risk for cardiovascular disease (10).
These agents are being increasingly
used off-label in management of type 1
diabetes (11) and are currently under
review by the U.S. Food and Drug Ad-
ministration as well as by the European
Medicines Agency as an adjunct to insulin
therapy in adults with type 1 diabetes.
Decisions from the U.S. and European
agencies for sotagliflozin, an SGLT112
inhibitor, and dapagliflozin, an SGLT2 in-
hibitor, are expected in 2019. It should be
noted that ipragliflozin, an SGLT2 inhibitor
currently available in Japan, Korea, and
Thailand, has recently been approved in
Japan to be coadministered with insulin
to adults with type 1 diabetes (12).
In adults with type 1 diabetes, SGLT
inhibitor therapy with dapagliflozin
added to intensified insulin therapy
showed moderate efficacy, reducing
A1C by ;0.4% (4.4 mmol/mol) at
6 months and ;0.3% (3.3 mmol/mol)
at 12 months while demonstrating im-
provement in time in range (70–180
mg/dL [3.0–10.0 mmol/L]) by continuous
glucose monitoring (CGM) without an
increase in time with hypoglycemia
(,70 mg/dL [,3.9 mmol/L]) (13–15).
Importantly, this benefit was demon-
strated in the setting of blinded studies
where patients treated with both SGLT
inhibitor and placebo had ongoing pro-
tocol-driven adjustments of basal and
bolus therapy (16). This improvement
in glycemia was achieved in the context
of;11.0% reduction of total daily insulin
dose compared with;8.0% reduction in
the placebo group (P , 0.0001). Inter-
estingly, although no substantial dose
dependency was observed for the im-
provement in glycemic control, weight
change did seem to be somewhat dose
dependent (16). Moderate weight loss
(;3.2% at 6 months and ;3.5% at 12
months)was seenwith theSGLT inhibitor
as compared with placebo (;0.1%) (16).
The EASE (Empagliflozin as Adjunctive
to inSulin thErapy) phase 3 program
included two double-blind, placebo-
controlled trials investigating the efficacy
and safety of empagliflozin as an adjunct
to insulin therapy in adults with type 1
diabetes (17). Significant reductions in
A1Cwere observed at the three empagli-
flozin doses studied: 2.5 mg (20.28%
[3.1 mmol/mol]), 10 mg (20.54% [5.9
mmol/mol]), and 25 mg (20.53%
[5.8 mmol/mol]), all P , 0.0001, with
no increase in hypoglycemia. Significant
reductions inweight, bloodpressure, and
total daily insulin dose were also ob-
served in the empagliflozin treatment
groups. Treatment with sotagliflozin
(SGLT112 inhibitor) showed similar re-
ductions in A1C, weight, systolic blood
pressure, and total daily insulindose (18).
In studies that included patient-
reported outcomes or quality of life
assessment, significant benefits were
associated with SGLT inhibition in
type1diabetes (19,20). Results regarding
the incidence or rate of severe hypogly-
cemia were somewhat mixed, but, in
general, the expected increase in severe
hypoglycemia in the context of the
greater reduction in A1C with the
SGLT inhibitor was not observed. CGM
further revealed improved time in range,
generally ;3 h/day, with all three SGLT
inhibitors (sotagliflozin, dapagliflozin,
empagliflozin) studied at the highest
dose, without an increase in time in
hypoglycemia.
Although SGLT inhibitor therapy has
shown improvements in glycemic con-
trol, weight loss, and other risk reduc-
tions, current studies have reported
a significant increase in the risk for
DKA (13–15,17,21,22), which appears
to be dose dependent (13–15,17).
Supplementary Table 1 presents infor-
mation about the differences in DKA
adjudication definitions. Supplementary
Tables 2–4 review the clinical data of the
pivotal trials for SGLT inhibitors in type 1
diabetes. The definitions for probable/
possible/potential events were very dif-
ferent between the programs, and the
trigger event identification process to
identify potential events differed. There-
fore, a direct comparison between the
programs is difficult. Supplementary Fig. 1
presents a common process for DKA
monitoring and adjudication in clinical
studies. Importantly, some study partic-
ipants who experienced DKA presented
with only slightly elevated glucose levels, a
condition referred to as euglycemic DKA
(euDKA). When euDKA occurs, the usual
clinical alert provided by hyperglycemia
is absent and many case reports have
demonstrated substantial delays in rec-
ognition, diagnosis, and treatment.
The Advanced Technologies & Treat-
ment for Diabetes (ATTD) Congress
convened a consensus conference in
June 2018, with an international panel
of 26 physicians and researchers with
expertise in using SGLT inhibitor therapy,
to develop strategies to mitigate DKA and
euDKA risk. Following the conference,
24 participants completed an online sur-
vey to better delineate areas of consen-
sus and areas of disagreement, including
appropriate cut points for DKA diagnosis,
risk factors, patient selection, and pa-
tient management. This review summa-
rizes our consensus recommendations
and key considerations for the safe use
of SGLT inhibitors in patients with type 1
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diabetes. Scientific questions requiring
further research are also identified.
BACKGROUND
Ketoacidosis With SGLT Inhibitors in
Type 1 Diabetes: Possible Mechanisms
Several mechanisms likely operate to
predispose individuals with type 1
diabetes to develop ketosis (increased
levels of b-hydroxybutyrate and
acetoacetate) and ketoacidosis in the
setting of SGLT inhibitor therapy. The
reduction of total daily insulin doses and
particularly basal insulin in patients trea-
ted with an SGLT inhibitor may cause
failure to suppress lipolysis and ketogen-
esis even if blood glucose levels do not
rise (23,24). SGLT inhibitors are associ-
ated with an increase in glucagon, per-
haps as a result of urinary glucose loss or
through direct action upon pancreatic
a-cells, which increases lipolysis and ke-
togenesis (25,26). The balance of glucagon
and insulin are critical to regulating these
metabolic pathways (23,27–29). It has also
been proposed that SGLT inhibitors de-
creaserenalclearanceofketonebodies(23).
Starvation ketosis, which is also me-
diated by reduced insulin levels and in-
creased glucagon levels, can occur in
individuals without diabetes with pro-
longed periods of fasting or very low-
carbohydrate diets (often referred to
as ketogenic diets) and is accelerated
by physical activity, physiological stress
(e.g., infection or pregnancy), and alco-
hol consumption. SGLT inhibition, by in-
creasing urinary glucose loses, may be
causing a pharmacologic push toward
ketosis, particularly when the behavioral
and physiological factors mentioned are
present (23,30). Readers are referred
elsewhere for a comprehensive review
of the physiology and pharmacology of
this system (23,31).
Diagnosing DKA
The spectrum of ketosis (measured ke-
tones in the blood or urine) to ketoaci-
dosis (ketosis associated with anion gap
metabolic acidosis) is quite broad, in-
volving an approximately 10-fold range
of ketone body concentration. The in-
crease in ketonemia and ketonuria is not
due to reduced renal ketone excretion
(9) unless there is severe dehydration
(hence, frequently with DKA).
DKA is usually associated with hyper-
glycemia in individuals with diabetes and
serum ketones .3.0 mmol/L. Similar to
DKA, the development of euDKA is char-
acterized by anion gap metabolic acido-
sis, ketonemia, and ketonuria but with
normal or modestly elevated blood glu-
cose levels (,250 mg/dL [13.9 mmol/L])
(31,32). As such, patients can present
with full-blown DKA but with glucose
levels ,250 mg/dL (,13.9 mmol/L).
Table 1 lists the levels of serum/urine
ketones that are associatedwith concern
and what should be done in response to
those values.
APPROACHES TO PREVENTION OF
DKA RELATED TO SGLT INHIBITOR
THERAPY
Patient Selection
Selection of appropriate patients for
SGLT inhibitor therapy is critical for min-
imizing DKA risk. The paramount criterion
for patient selection is presentation with
normal ketone levels (,0.6 mmol/L
blood ketones; negative urine ketones).
However, the risk factors associated with
each patient’s lifestyle/behaviors (Table
2) and willingness/ability to follow pre-
scribed regimens for monitoring ketones
and responding appropriately to ele-
vated ketone levels when present must
also be considered (Table 3).
As a general guideline, SGLT inhibitor
therapy should not be used in patients
using low-carbohydrate or ketogenic
diets as, anecdotally, they seem to be
at increased risk of adverse ketosis
effects and certainly create a diagnostic
dilemma in evaluating the clinical sig-
nificance of ketosis. Also, with regard to
diet, patients who skip meals and/or
consume excessive alcohol seem to be
at increased risk. Patients who use an
insulin pump are also at increased risk
because of the possibility of pump or
insulin infusion set malfunction. Patients
with type 1 diabetes who miss insulin
doses, have recurrent episodes of DKA,
or experience prolonged significant hy-
perglycemia (particularly .350 mg/dL)
and/or display low engagement with
their diabetes regimen are certainly at
high risk of DKA when on SGLT inhibitor
therapy. However, these patients may be
considered candidates if they can dem-
onstrate thesustainednecessarychanges
in lifestyle and self-management behav-
iors, as well as monitor their capillary/
urine ketone levels.
Because adequate studies of SGLT in-
hibitors have not been performed in
pregnant women, SGLT2 inhibitors should
Table 1—Cut points for ketosis/DKA and corresponding remedial actions
Blood ketone (BHB) level Urine ketone* Remedial actions
,0.6 mmol/L (normal) Negative No action needed
0.6–1.5 mmol/L (ketonemia) Trace or small Treat as follows or per clinician instructions:
c Ingest 15–30 g rapidly absorbed carbohydrate and
maintain fluid consumption (300–500 mL) hourly
c Administer rapid-acting insulin based on carbohydrate
intake (hourly)
c Check blood/urine ketones (every 3–4 h) until resolution
c Check blood glucose frequently to avoid hyperglycemia
and hypoglycemia
Seekmedical attention if levelspersist andsymptomspresent
1.6–3.0 mmol/L (impending DKA) Moderate Follow treatment recommendations listed above
Consider seeking immediate medical attention
.3.0 mmol/L (probable DKA) Large to very large Seek immediate medical attention
BHB, b-hydroxybutyrate. *Urine ketone concentrations are dependent on hydration and other factors; these values do not closely correlate
with blood BHB levels.
not be used in pregnant women with type
1 diabetes as pregnancy is associated
with an increased risk of ketoacidosis,
which is associated with a high risk of
fetal mortality (33). No data are currently
available on use of SGLT inhibitor therapy
in children and youth ,18 years of age
with type 1 diabetes.
Insulin Dose Adjustments
When initiating SGLT inhibitor therapy in
individuals with type 1 diabetes, insulin
must be reduced cautiously in order to
prevent ketosis and DKA. In clinical trials
of SGLT2 inhibitors, the proportional
dose reductions seen for basal and bolus
insulin were similar (13,14) or reductions
were primarily in basal insulin doses (34).
However, when using sotagliflozin, the
dose reductions observed in the clinical
trialswere largely in theprandial ormeal-
associated insulin (18). Therefore, the
clinician needs to individualize such re-
ductions for each patient based primarily
on degree of hyperglycemia as well as the
specific SGLT inhibitor used.
In patients who are relatively well con-
trolled (A1C ,7.5% [,58 mmol/mol]),
10–20% reductions in insulin doses, ac-
companied by frequent blood glucose
monitoring or CGM, and rapid readjust-
ment with health care provider input are
recommended. Some patients may need
to decrease their carbohydrate intake in
order to accommodate the reduced insulin
dose as long as ketone levels do not rise.
Others may need to increase their carbo-
hydrate intake in order to maintain ade-
quate exogenous insulin levels to prevent
ketosis. Adjustments in insulin doses should
be made at least every 24–48 h initially.
For less well-controlled patients (A1C
$7.5% [$58 mmol/mol]), only slight or
no reductions in prandial and basal in-
sulin may be needed. Determination of
which insulin doses should be reduced
should be based on detailed assessment
of blood glucose profiles or, preferably,
CGM data as well as hypoglycemia his-
tory and awareness.
Initiation and Dosing of SGLT
Inhibitors
As discussed, blood ketone (b-
hydroxybutyrate) levels should be
,0.6 mmol/L prior to initiating SGLT
inhibitor therapy. If blood ketones are
$0.6 mmol/L, additional baseline blood
ketone values should be obtained to
determine whether the elevated ketones
are normal for the patient (due to lifestyle
factors) or an indication of chronic in-
adequate insulin coverage in the fasting
state.
We recommend that SGLT inhibitor
therapy be initiated at the lowest dose
available. Some suggest even splitting
tablets for the currently marketed SGLT2
inhibitors to get to lower-than-marketed
doses. Patients who have a good ex-
perience with low-dose SGLT inhibitor
therapy could be considered for dose
escalation based on clinical response.
As observed in clinical trials, lower
doses of SGLT inhibitors are associated
with reasonable efficacy and lower risks
of DKA (13,14). Specifically, the EASE
program included a lower dose (i.e.,
empagliflozin 2.5 mg), which is not cur-
rently available, in addition to the doses
approved for use in patients with type 2
diabetes (i.e., empagliflozin 10 and25mg)
(17). The ketoacidosis rate was compa-
rable between empagliflozin 2.5 mg and
placebo but increased with doses of 10 mg
and 25 mg. These data suggest that SGLT2
inhibitor dose selection itself is an important
factor in terms of DKA risk mitigation.
Ketone Monitoring
Ketone testing is required because de-
velopment of euDKA cannot be detected
by glucose monitoring. Although labora-
tory testing is the most precise method
for assessing b-hydroxybutyrate levels in
the clinical settings (35), self-testing via a
blood ketone meter or urine testing is
sufficient for patient use in detecting
ketosis and early development of DKAd
blood ketone (b-hydroxybutyrate) con-
centrations .0.6 mmol/L or trace (or
greater) urine ketones (acetoacetate).
We recommend patient self-
measurement of capillary blood ketones,
specifically b-hydroxybutyrate (the most
prevalent ketone body) as a matter of
routine in assessing the metabolic state
of patients with type 1 diabetes treated
with SGLT inhibitors (36–40). In patients
who cannot afford or do not have access
to capillary blood ketonemeasurements,
urine ketone measurements are accept-
able.However, itmustbe recognized that
the urine test only measures acetoace-
tate,notb-hydroxybutyrate,andestimation
of urine ketones will be an average of the
concentration within the urine held in
the bladder since the last void (41).
Table 3—Patient criteria for SGLT
inhibitor therapy
c .18 years of age
c Adherent to prescribed diabetes regimen
c Willing/able to perform all prescribed
diabetes self-management tasks
c Performs blood glucose monitoring or
uses CGM as prescribed
c Willing/able to perform ketone testing as
prescribed
c Has received education/training in
ketone testing and interpreting/acting
upon test results
c Has access to ketone testing materials
c Has immediate access to a clinician if
blood or urine ketone levels are elevated
c No or moderate use of alcohol; no use of
illicit drugs
c Unimpaired cognition
c Not pregnant or wanting to become
pregnant
Table 2—Risk factors for DKA associated with SGLT inhibitor therapy
Risk level for DKA Factor
Moderate/high c Reduced basal insulin by more than 10–20%
c Insulin pump or infusion site failure
c Reduced or inconsistent carbohydrate intake
c Excessive alcohol use
c Use of illicit drugs
c Volume depletion/dehydration
c Acute illness of any sort (viral or bacterial)
c Vomiting
Low/moderate c Vigorous or prolonged exercise
c Reduced prandial insulin dose by more than 10–20%
c Travel with disruption in usual schedule/insulin regimen
c Insulin pump use
Minimal/low c Low BMI (,25 kg/m2)
c Inconsistent caloric intake
c Moderate alcohol use*
c Female sex
*If ketone levels increase from baseline.
Moreover, urine output is frequently low
in patients with DKA due to dehydration,
and it may take several hours until urine
is produced again, which may delay
appropriate treatment (41). Because
b-hydroxybutyrate is oxidized to aceto-
acetate with treatment of DKA, urine
ketone readings will rise with treatment
even if bloodb-hydroxybutyrate concen-
trations are dropping (41). The paradox-
ical rise in urine ketones could give the false
impression that the DKA is not resolving.
Patients should not rely on a single
ketone measurement for definitive deter-
mination of their metabolic state. In pa-
tients with elevated ketones, glucose and
ketone measurements should be re-
checked every 1–3 h to ensure resolution
of ketonemia/ketonuria. Symptoms of
ketosis do not correlate well with ketone
levels, which can increase rapidly.
Currently, there is no evidence to sup-
port specific testing regimens. However, it
is the consensus of the group that ketone
testing frequency should be individualized
according to the patient’s lifestyle and/or
risk factors after initiating therapy. How-
ever, for all patients, we recommend that
ketones be measured with any symptoms
consistent with DKA, including malaise,
fatigue, nausea, and vomiting. Ketones
should also be measured with changes
in diet, activity, or insulin dose as well
as for concomitant events such as in-
fection, dehydration, surgery, injury,
pump occlusion/malfunction, or stress.
It should be noted that treatment with
SGLT inhibitors in patients using insulin
pumps with automated features, includ-
ing low-glucose insulin suspend and hy-
brid closed-loop, has not been well
studied. Ketones should be measured re-
petitively for as long as symptoms persist
or stressors remain. Random or periodic
measurement of ketones is also recom-
mended to ensure that ketone testing sup-
plies are readily available and not expired.
Holding or Discontinuing SGLT
Inhibitor Therapy
Anynausea, vomiting, orabdominaldiscom-
fort should prompt discontinuation of SGLT
inhibitor therapy and evaluation of ketosis.
SGLT inhibitor therapy should be withheld
immediately if the patient is hospitalized,
acutely ill, or unable to eat and drink nor-
mally. SGLT inhibitors should bewithheld or
discontinuedprior toanymedicalprocedure
(ideally for 3 days), particularly if the patient
will be reducing food intake or will not be
allowed toeat ordrink for some timebefore
and after the procedure.
For patients who are switching their
type of insulin therapy (e.g., injections to
insulin pump therapy) or changing from
manual mode to automode on an auto-
mated insulin delivery system, it is pru-
dent that they hold their SGLT inhibitor
until their insulin doses are adjusted,
blood glucose is controlled, and ketone
levels are normal.
DKA Prevention
When elevated ketones are present,
patients should be instructed to first
discontinue SGLT inhibitor therapy until
ketones are back to baseline. Treatment
must be initiated swiftly once elevated
ketones are identified in order to avoid
DKA and potential hospitalization. The
key to treatment of ketosis is for patients
to inject insulin and consume carbohy-
drates, as well as maintain adequate
hydration. Even if the patient is on an
insulin pump, it is often best to provide
insulin by injection as the first step in
treatment. If on insulin pump therapy, it
is very important for patients to begin to
troubleshoot the pump and give insulin
by injection until they are sure that the
insulin pump is delivering insulin and any
pump or infusion set issues are resolved.
Recommendations for DKA prevention
are presented in Table 1.
DKA Treatment
If the symptoms and/or ketones are wors-
ening, the patient should seek immediate
medical assistance.Whether to send a pa-
tient for further medical evaluation needs
to be decided individually for each patient
based upon specific characteristics and
may need to occur sooner in the presence
of additional comorbidities, such as car-
diovascular disease or pneumonia. If pa-
tients go to the emergency department or
an urgent care center, they should inform
themedical personnel that they have type
1 diabetes and are on an SGLT inhibitor,
which means they may have DKA with
a relatively normal glucose level. Patients
should have an evaluation that includes
measurements of capillary/venous pH,
blood bicarbonate, anion gap, and blood
ketones (b-hydroxybutyrate).
Patient and Clinician Education
Patients
All patients should receive thorough in-
struction in DKA risk factors, ketone
monitoring, and treatment protocols.
This is especially important for patients
for whom administration of both insulin
and carbohydrates is counterintuitive
when glucose levels are only slightly
elevated.
Patients should also be instructed
about anticipated situations in which
they may wish to hold their SGLT
inhibitor. This includes such events
as increased physical activity and sit-
uations where they may become de-
hydrated or they choose to alter their
dietary intake or consume more alco-
hol. Therefore, it is important that
patients become familiar with how
these factors impact their ketone lev-
els. Importantly, patients should be
empowered tomake decisions regarding
whether or not to stop their SGLT in-
hibitor. Stopping it for aday, if in doubt, is
prudent and should not cause significant
metabolic issues.
All patients treatedwith SGLT inhibitor
therapy should be provided with educa-
tional materials (e.g., wallet cards, re-
frigerator magnets, etc.) that can serve
as reminders regarding risk factors and
provide “quick reference” resources for
treatment.
Clinicians
Only practitioners knowledgeable in
these principles should prescribe
SGLT inhibitor therapy in people with
type 1 diabetes. In themedical settings,
DKA should be considered in all patients
taking SGLT inhibitors who present with
typical symptoms of DKA even when
glucose levels are normal. Because cur-
rent guidelines for treatment identify
DKA as a hyperglycemic emergency, it
is important that emergency depart-
ments are made aware that DKA can
presentwithout overtly elevated glucose
levels in patients treated with SGLT in-
hibitors. This message must be part of all
professional education initiatives. Edu-
cational components of a risk mitigation
strategy when introducing SGLT inhibi-
tors for type 1 diabetes are summarized
in Table 4, which includes the STICH
protocol for risk mitigation (42).
RESEARCH QUESTIONS
Because much of the evidence for DKA
risk has been garnered from randomized
clinical trials with highly selected pa-
tients, additional research is needed to
evaluate the efficacy and DKA risk of SGLT
inhibitors in larger cohorts of patients
with type 1 diabetes, using real-world
methodologies. It is also important to
develop a better understanding of the
apparent dose-dependent effect in both
increased efficacy and increased DKA
rates associated with higher doses of
SGLT inhibitors. Currently available stud-
ies (13,22) suggest these relationships
but were not definitive.
Another question that warrants fur-
ther investigation is whether patients with
extremely elevated A1C levels (.10% [86
mmol/mol]) should receive treatmentwith
SGLT inhibitors. The 5-year follow-up data
from the T1D Exchange reported signifi-
cantly higher (.15%) incidence of DKA in
patients with A1C above 10% (86 mmol/
mol) but not treatedwith an SGLT inhibitor
(43).Althoughsomebelieve it is reasonable
to recommend this therapy to all patients
who are both willing and able to monitor
ketones as prescribed and take the appro-
priate remedial steps as needed, some
clinicians recommend adjusting insulin
therapy to reduce A1C levels prior to
initiation of SGLT inhibitor treatment,
and others recommend not using these
agents in anyone with an A1C .10% (86
mmol/mol). Additional data are needed to
determine whether elevated A1C is an
independent risk factor for DKA in patients
who aremeticulous in their diabetes self-
management.
Developing an evidence base and al-
gorithms to support decisions on reduc-
ing insulin doses should also be a priority
for future research. Although the recom-
mendations for insulin adjustment pre-
sented in this Consensus Report are
based on clinical trial experience, clinical
judgment, and real-world experience
with SGLT inhibitor therapy, more de-
finitive approaches are needed to match-
ing each formulation and dosage to
reductions in the most appropriate in-
sulin (prandial or basal) and to establish-
ing the degree of reduction that will
lessen DKA risk. There is a strong case
for a clinical evaluation of the guidance
presented here.
Determination of optimal frequency of
ketonemonitoring and how andwhen to
respond to ketone levels that rise above
the normal range also remain as ques-
tions for further investigation. Although
daily ketone testingmay reduceDKA risk,
this approach could also lead to lower
adherence if ketone levels aremostly low
or zero and the patient does not feel that
this frequency of monitoring is needed
(44).Moreover, there is no evidence that
daily ketone monitoring actually pre-
vents DKA; available clinical trials in
patients with type 1 diabetes did not
use protocols that included daily moni-
toring of ketones. Cost also represents a
major barrier to increased frequency of
ketone monitoring, which could further
discourage patients from the practice.
Although urine ketone strips are conve-
nient andmuch less expensive than blood
ketone meters/strips ($0.20 vs. $2.09 per
strip, not including the cost of the blood
ketone meter) (45), the sensitivity and
specificity of the urine test for DKA are
substantially less than those of blood
ketone measurement (41).
Finally, we recommend evaluation of
both patient and clinician education pro-
grams and materials. Although educa-
tional interventions for basic DKA
prevention in type 1 diabetes appear
to be effective, many patients are not
familiar with ketone testing and DKA. It
will be important to evaluate the efficacy
and usability ofmaterials specific to SGLT
inhibitor therapy. At the very least, in-
sulin pump–treated patients must be
convinced that a “glucocentric” approach
to identifying infusion site problems is
not appropriate when receiving adjunc-
tive therapy with an SGLT inhibitor.
CONCLUSIONS
SGLT inhibitor therapy is a promising
option for adjunctive therapy in the
treatment of type 1 diabetes. Studies
in this population have already demon-
strated that use of SGLT inhibitors con-
fers significant benefits, including
improved glycemic control, increased
time in range, improved quality of life
measures, and weight loss (13,18,22).
Moreover, the cardiovascular and renal
benefits demonstrated in the type 2 di-
abetes trials (7,8) may be a class effect
that positively impacts all patients re-
gardless of the type of diabetes.
As observed in clinical trials, the rate of
DKA in the placebo arm is substantially
less than incidence rates from the latest
registries where the incidence of DKA
with SGLT inhibitor therapy is relatively
low. The increase in the absolute risk in
SGLT inhibitor–treated patients versus
placebo-treated patients was in the
range of 4%per year, and in these clinical
patients it was lower than reported in
general practice but still higher than seen
Table 4—Educational components of a risk mitigation strategy when introducing
SGLT inhibitors for type 1 diabetes
Patient education c All patients initiating SGLT inhibitor therapy should receive
through training/education in the following areas:
◦DKA causes and symptoms
◦Euglycemic ketoacidosis
◦Importance of ketone monitoring
◦Use of ketone monitoringdtraining in testing
procedure, proactive monitoring, situations when
monitoring is indicated
◦Treatment protocol for addressing ketosis
◦Guidance in when to seek medical attention
Clinician education c All prescribing clinicians should acquire full understanding
of the safe use and risks associated with SGLT inhibitor
therapy:
◦Criteria for patient selectiondbaseline ketone level,
demographic/behavioral considerations
◦Training/educational needs of patientsddetection
(ketone levels, symptoms), prevention strategies,
treatment
◦Potential for missed DKA, euDKA
◦Treatment strategiesdSTICH protocol recommended:
▪ STop SGLT inhibitor treatment for a few days
▪ Insulin administration
▪ Carbohydrate consumption
▪ Hydration with a suitable drink (e.g., water or
noncaloric athletic drink with balanced electrolytes)
Risk Communication c Product labeling, website
c Health care professional education
c Medication guide, patient alert card*
*See Supplementary Fig. 4.
with placebo. The potential benefits of
SGLT inhibitors for people with type 1
diabetes appear clinically meaningful.
Thus, strategies for mitigating DKA risk
are vital to the adoption and safe use of
SGLT inhibitors in all diabetes popula-
tions, particularly those requiring insulin.
The consensus recommendations pre-
sented herein are based on current evi-
dence fromclinical trials andourexpertise
and experience using SGLT inhibitors
with our patients with type 1 diabetes.
Our goal is to provide a starting point for
the safe use of SGLT inhibitor therapy in
this population and to encourage addi-
tional investigations that will provide
more comprehensive, evidence-based
guidance for clinicians and patients.
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